Inclusion Criteria:~* Male or female, aged 55-75 years (both inclusive) at the time of signing the informed
consent~* Mild cognitive impairment (MCI) or mild dementia of the Alzheimer's type according to the National
Institute on Aging- Alzheimer's Association (NIA-AA) 2018 criteria~* Clinical dementia rating (CDR) global
score of 0.5 or 1 at screening (visit 1)~* Amyloid positivity established with either historical amyloid
positron emission tomography (PET) or historical cerebrospinal fluid (CSF) AÎ²1-42 or historical CSF
AÎ²1-42/AÎ²1-40 (historical data within the last 5 years) or blood sample for amyloid biomarker (AÎ²42/AÎ²40
ratio and p-tau217/np-tau217 ratio) at screening (visit 1)~* Treated with acetylcholinesterase inhibitors
(approved for the treatment of Alzheimer's disease) and on stable dose for greater than 90 days before
screening (visit 1)~
